Evidence map›Paper›PMID 40237878›Full record

ArticleBreast cancer research and treatment2025

Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer.

Connie Lau, Krista LaBorde, Bilqees Fatima, Shahad S Alfartosy, Susan Abughosh, Rodrigo De La Torre, Erika N Brown, Meghana V Trivedi

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Connie LauDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 4349 Martin Luther King Blvd, Houston, TX, 77204-5000, USA.
Krista LaBordeDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 4349 Martin Luther King Blvd, Houston, TX, 77204-5000, USA.
Bilqees FatimaDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, 4349 Martin Luther King Blvd, Houston, TX, 77204-5000, USA.
Shahad S AlfartosyDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 4349 Martin Luther King Blvd, Houston, TX, 77204-5000, USA.
Susan AbughoshDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, 4349 Martin Luther King Blvd, Houston, TX, 77204-5000, USA.
Rodrigo De La TorreHouston Methodist Willowbrook Hospital, 18220 State Hwy. 249, Houston, TX, 77070, USA.
Erika N BrownHouston Methodist Willowbrook Hospital, 18220 State Hwy. 249, Houston, TX, 77070, USA.
Meghana V TrivediDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 4349 Martin Luther King Blvd, Houston, TX, 77204-5000, USA. mtrivedi@central.uh.edu.ORCID http://orcid.org/0000-0002-0585-5580

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy improve survival in patients with hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer (BC). This retrospective study aimed to evaluate CDK4/6i adherence, factors associated with non-adherence, the impact of health-system specialty pharmacy on adherence, and effects of non-adherence on survival outcomes in HR + /HER2- BC patients.

methodsData was collected from Houston Methodist Hospital System (HM) from HR + /HER2- BC patients with medication fill history utilizing electronic medical records. CDK4/6i adherence was calculated using the mean possession ratio ≥ 80%. Multivariable logistic regression model and Kaplan-Meier analysis were utilized to evaluate factors associated with non-adherence and its impact on survival, respectively.

resultsA total of 121 patients were assessed and analyzed; 55% patients received abemaciclib, 40% were on palbociclib, and 4% were on ribociclib. More patients were on aromatase inhibitors and tamoxifen (79%) than fulvestrant (21%). Most of the patients were Caucasian (64%), non-Hispanic or Latino (84%), and postmenopausal (66%). Overall, 52 patients (43%) were non-adherent. Patients ≥ 65 years of age (OR: 0.304, [95% CI: 0.110-0.840], P-value: 0.022) and those of Hispanic or Latino ethnicity (OR: 0.291, [95% CI: 0.086-0.985], P-value: 0.047) were more likely to be non-adherent to CDK4/6i. Non-adherence to CDK4/6i was associated with worse overall survival and progression-free survival.

conclusion43% patients were non-adherent to CDK4/6i. Older patients and those of Hispanic ethnicity were more likely to be non-adherent. Non-adherent patients had worse survival outcomes, highlighting the unmet need to implement interventions to improve CDK4/6i adherence in these patients.

Indexed as

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Medication AdherenceProtein Kinase InhibitorsAdultAgedAged, 80 and overAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedPiperazinesabemaciclibAminopyridinesBenzimidazolesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespalbociclibPiperazinesProtein Kinase InhibitorsPurinesPyridinesReceptors, EstrogenReceptors, ProgesteroneribociclibBreast cancerCDK4/6 inhibitorsEndocrine therapyHormone receptor-positive/HER2-negativeMedication adherenceSpecialty pharmacy

Identifiers

PMID40237878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.